I CONSENT REFUSE COOKIES Home News Center Contact Fresenius Kabi Global Select Website Company About Us About CEO Michael Sen Living on Parenteral Nutrition Clinical Nutrition at Home Our Business Fields Locations Worldwide Africa Asia Pacific Europe Latin America Middle East North America Find Us History Publications MNI - Optimal Nutrition Care For All Transparency Initiative Quality Management Quality Management Certificates “caring for life” – in times of the coronavirus pandemic Home Company About Us About CEO Michael Sen About CEO Michael Sen Michael Sen, 53, joined the Management Board of Fresenius in April 2021 with responsibility for Fresenius Kabi. Before joining Fresenius Kabi, he was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin. Fresenius Kabi AG © November 2021 Go to top Sitemap Imprint Legal Disclaimer Data Protection

Home News Center Contact Fresenius Kabi Global Select Website Company About Us About CEO Michael Sen Living on Parenteral Nutrition Clinical Nutrition at Home Our Business Fields Locations Worldwide Africa Asia Pacific Europe Latin America Middle East North America Find Us History Publications MNI - Optimal Nutrition Care For All Transparency Initiative Quality Management Quality Management Certificates “caring for life” – in times of the coronavirus pandemic Home Company About Us About Us Fresenius Kabi at a glance Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies. Fresenius Kabi employs around 40,500 people worldwide. With our corporate philosophy of "caring for life", we are committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. In 2020, the company reported sales of around €7.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group. Key Figures € in millions 2020 2019 Sales 6,976 6,919 EBITDA1 1,490 1,573 EBIT1 1,095 1,205 Net Income1,2 730 797 Employees (Dec 31) 40,519 39,627 1 Before special items 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA Fresenius Kabi AG © November 2021 Go to top Sitemap Imprint Legal Disclaimer Data Protection